Cynthia X. Ma, MD, PhD, on Benefits of Attendance at AACR

Video

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

CancerNetwork® sat down with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, to discuss educational sessions at the American Association for Cancer Research (AACR) Annual Meeting 2021.

Transcript:

I really liked the educational sessions. It’s hard to listen to all the seminars and lectures and but I was able to listen to some of the on-demand sessions. One of those was in targeting DNA-damage repair pathways and immunotherapies, and I thought those were very helpful. I designed trials and see patients [and I] always want to be able to develop trials looking at the most cutting-edge research. We should be able to [do this], we are aiming at [what] translates to the clinic.

Recent Videos
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
Related Content